MedPath

Study of Dietary Composition in Crohn's Disease

Not Applicable
Recruiting
Conditions
Inflammatory Bowel Diseases
Crohn Disease
Interventions
Other: Anti-inflammatory diet
Other: Regular diet
Registration Number
NCT04431700
Lead Sponsor
University of California, Los Angeles
Brief Summary

Patients with inflammatory bowel disease (IBD) often have narrowed microbial diversity and altered composition and function of the gut microbiome. We anticipate the anti-inflammatory diet, when compared with the usual diet, to produce favorable changes in these multi-omics profiles. These findings will provide insight into the interactions between diet and host biology, while providing clues on the mechanisms of diet therapy's effect and CD pathogenesis.

Detailed Description

A randomized controlled trial of the anti-inflammatory whole food diet versus usual diet for the induction of remission in 104 adults with mild-to-moderate Crohn's Disease (CD). The anti-inflammatory whole food diet will be compared to participants usual diet for understanding its effects on achieving clinical remission, clinical response, reduction in serological and fecal markers of inflammation, and improvement in patient-reported outcomes, such as physical activity, anxiety, depression, fatigue, pain, sleep disturbance, social satisfaction, and quality of life. The study will involve collection of blood and fecal specimens to evaluate the effects of the anti-inflammatory diet on the gut microbiome, bacterial metabolome, innate immune markers, and fecal microRNA profiles. The participants will be placed on anti-inflammatory diet for 8 weeks and assessed every 2 weeks for adherence.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
116
Inclusion Criteria
  • Age of 18 to 75 years old
  • History of Crohn's Disease (CD) with mild to moderate symptoms and prior biopsy proof
Read More
Exclusion Criteria
  1. History or current diagnosis of any of the following:

    • Stroke or Arrhythmia
    • Seizures
    • Liver Disease
    • Untreated hypertension (High Blood Pressure)
    • Active malignancy
    • Bleeding disorders
    • Heart Disease
    • Lung disease
    • Previous Heart surgery
    • Previous Gastrointestinal Surgery
    • Kidney Disease
    • Chronic Diarrhea
    • End enterostomy
    • Bulimia
    • Anorexia
    • Laxative Abuse
    • Endocrine Disorder
    • Current history of smoking tobacco
    • Urgent need for abdominal sugery
    • Severe Malnutrition
    • Active alcohol or non-cannabinoid substance abuse
  2. Recent hospitalization within the last 30 days

  3. Currently pregnant of lactating.

  4. Current use probiotics or dietary supplements that would not be willing to discontinue for the length of the study.

  5. Concerns for non-compliance

  6. If currently on immunosuppressants, immunomodulators, cotticosteroids, and/or 5-aminosalicylates, no changes in doses will be permitted during the trial except for tapering of corticosteroids.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Anti-inflammatory whole foodAnti-inflammatory dietIncluded food items will include a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., curcumin), fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be permitted or encouraged. Recommended portions of complex carbohydrates (50% - 60%) and lean proteins (20% - 30%) will form the basis of weight-based caloric needs. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Vegetables with high insoluble fiber content will be cooked instead of eaten raw.
Regular DietRegular dietPatients in the control diet arm will be counseled to continue their regular diets and focus on recording all food intake.
Primary Outcome Measures
NameTimeMethod
Efficacy of the anti-inflammatory whole food diet for the induction of remission in Crohn's Disease8 weeks

The patients' clinical response, defined by the Harvey-Bradshaw Index (HBI) (5 through 16 points) for clinical symptom improvement and/or remission.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UCLA Center for Human Nutrition, 1000 Veteran Ave.

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath